← Eichor
Study identifier: NCT03830788 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

Condition: Prostate Cancer  ·  Sponsor: Center Eugene Marquis

PhaseNA
Planned participants240
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly focused on the issue of erectile dysfunction. A total of 240 potent patients are randomized in two arms. The experimental arm consists of SBRT delivering 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. The control arm consists of brachytherapy by Iodine 125 delivering 144 Gy to the prostate. The main objective of this health economics study is to perform a cost-utility analysis of SBRT compared to "standard" Iodine 125 brachytherapy in low-risk prostate cancer, 3 years after treatment. The endpoint is the Incremental Cost-Utility Ratio (ICUR) between SBRT and brachytherapy as primary criterion, expressed in cost per quality adjusted life year (QALY) gained. Cost-effectiveness analyses are performed as secondary objective with Incremental Cost-Effectiveness Ratios (ICERs) expressed as cost per erectile dysfunction avoided and cost per Life Year Gained. A long term evaluation is also performed, including a cost-utility, cost-effectiveness and budget impact analysis at 5 years, a comprehensive assessment of the erectile dysfunction up to 5 years after treatment, an evaluation of acute and late genito-urinary (GU) and Gastro-Intestinal (GI) toxicities, and of quality of life up to 5 years after treatment. Eight patients/year/center are expected to be recr…

This description comes directly from the study's public registry record.

Talk to the study team

Martine Gestin, PhD  ·  +33(0)299253036  ·  m.gestin@rennes.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (20)

Clinique Claude BernardAlbi, FranceNot Yet Recruiting
ICO Paul PapinAngers, FranceRecruiting
Institut BergoniéBordeaux, FranceNot Yet Recruiting
Polyclinique Bordeaux-AquitaineBordeaux, FranceRecruiting
CLCC Georges-François LeclercDijon, FranceRecruiting
Centre Amethys - Charlebourg - La DéfenseLa Garenne-Colombes, FranceRecruiting
Centre de Cobalthérapie HartmanLevallois-Perret, FranceNot Yet Recruiting
CH Lyon SudLyon, FranceTerminated
Institut régional du Cancer de MontpellierMontpellier, FranceNot Yet Recruiting
Institut CurieParis, FranceRecruiting
Hôpital Lyon SudPierre-Bénite, FranceTerminated
Institut Jean GodinotReims, FranceNot Yet Recruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03830788